High-quality compounded semaglutide maintains pharmaceutical-grade purity and is tested for safety and potency
Women experiencing menopause before age 45 (early menopause) or before age 40 (premature ovarian insufficiency) require specialist referral
Notably, the drug appears to outperform dietary interventions in improving endothelial and cardiac function in obesity-associated heart failure, possibly via modulation of inflammatory pathways, immune cell responses, and adipose tissue remodeling [123]
Honorable Mention: Mounjaro (tirzepatide) Indication(s): Type 2 diabetes, chronic weight management Manufacturer(s): Eli Lilly 2024 Sales (USD): $11.54 billion 2025 Outlook: While Mounjaro itself is not approved for weight loss, it drove significant off-label use before Zepbounds launch and helped set the stage for the obesity-focused branding strategy that now powers Lillys market dominance
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward to minimize gastrointestinal side effects
